MIBI as prognostic factor in breast cancer

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 1, 2003, Pages 46-50

  Del Vecchio, S ^a   Zannetti, A ^a   Aloj, L ^a   Salvatore, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Breast neoplasms, diagnosis; Breast neoplasms, radionuclide imaging; Radiopharmaceuticals

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MITOMYCIN C; PROTEIN BCL 2; TRACER;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG RESPONSE; DRUG UPTAKE; FUNCTIONAL ASSESSMENT; HUMAN; LUNG CANCER; LYMPHOMA; META ANALYSIS; MULTIDRUG RESISTANCE; PHENOTYPE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SARCOMA; SCINTISCANNING;

BREAST NEOPLASMS; HUMANS; METABOLIC CLEARANCE RATE; PROGNOSIS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME;

EID: 0038354631     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Eary JF, Krohn KA. Positron emission tomography: Imaging tumor response. Eur J Nucl Med 2000;27:1737-9.
2. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-38.
3. Delmon-Moingeon LI, Piwnica-Worms D, Van Den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198-202.
4. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
5. Bradshaw DM, Arceri RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-90.
6. Ballinger JR. Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein. Cancer Biother Radiopharm 2001;16:1-7.
7. Del Vecchio S, Ciarmiello A, Salvatore M. Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm 2000;15:327-37.
8. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, Van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434-42.
9. Kapucu LO, Akyuz C, Vural G, Oguz A, Atasever T, Buyukpamukcu M et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 1997;38:243-7.
10. Kao CH, Tsai SC, Wang JJ, Ho YJ, Ho ST, Changlai SP. Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors. Br J Haematol 2001;113:369-74.
11. Bom HS, Kim YC, Song HC, Min JJ, Kim JY, Park KO. Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med 1998;39:91-4.
12. Yamamoto Y, Nishiyama Y, Satoh K, Takashima H, Ohkawa M, Fujita J et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 1998;39:1626-9.
13. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Lee JK. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin Cancer Res 2000;6:820-4.
14. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
15. Moretti JL, Azaloux H, Boisseron D, Kouyoumdjian JC, Vilcoq J. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 1996;23:980-6.
16. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 1997;38:1003-8.
17. Del Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150-9.
18. Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-83.
19. Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of chemotherapeutic response by technetium 99m-MIBI scintigraphy in breast carcinoma patients. Cancer 2001;92:232-9.
20. 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT. J Nucl Med 1999;40:1778-83.
21. Nishiyama Y, Yamamoto Y, Fukunaga K, Kiuchi T, Satoh K, Takashima H et al. Evaluation of radiotherapeutic response in non-small cell lung cancer patients by technetium-99m MIBI and thallium-201 chloride SPET. Eur J Nucl Med 2000;27:536-41.
22. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000;10:369-77.
23. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59:1693-700s.
24. 99mTc-MIBI uptake and Bcl-2 overexpression in untreated breast cancer patients. Eur J Nucl Med 2001;28:1120.